Clinical Trial Update: Open-Label Study of Efficacy and Safety of Recombinant Human N-acetylgalactosamine 4-sulfatase in Patients With MPS VI [Phase 2]

View source ↗

Summary

Open-label Phase 2 study evaluating the efficacy and safety of Naglazyme (recombinant human N-acetylgalactosamine 4-sulfatase) in patients with Mucopolysacchari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucopolysaccharidosis Type Vi

Drugs mentioned

• NAGLAZYME (GALSULFASE)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis VI | Phase 2 | Status: COMPLETED